(Q81038996)
Statements
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers (English)
Mark C Willingham
Raffit Hassan
Susie Bullock
Ahalya Premkumar
Robert J Kreitman
Hedy Kindler